• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    (OP: ESAIY )

    8.200 UNCHANGED
    Streaming Delayed Price Updated: 3:59 PM EST, Nov 6, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 8.200
    Bid (Size) N/A (0)
    Ask (Size) N/A (0)
    Prev. Close 8.200
    Today's Range 8.200 - 8.200
    52wk Range 8.000 - 13.57
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Week In Review: Multitude Out-Licenses Tissue Factor ADC To Adcendo In $1 Billion Deal
    Shanghai Multitude Therapeutics out-licensed global rights for its Tissue Factor ADC to Adcendo in a $1 billion agreement. The value of the agreement includes upfront and milestone payments, with... 
    Via Talk Markets
    Biogen's Alzheimer's Drug Secures UK Approval, But An Independent Agency Does Not Recommend Reimbursement
    The U.K.'s Medicines and Healthcare products Regulatory Agency approved Eisai and Biogen's Leqembi for treating mild cognitive impairment and mild dementia due to Alzheimer's. Despite this, NICE stated... 
    Via Benzinga

    Performance

    YTD
    -33.63%
    -33.63%
    1 Month
    -11.64%
    -11.64%
    3 Month
    -11.16%
    -11.16%
    6 Month
    -22.71%
    -22.71%
    1 Year
    -36.87%
    -36.87%

    More News

    Read More
    Week In Review: Eisai Enters $1.5 Billion Molecular Glues Pact With SEED
    Via Talk Markets
    Biogen Stock Tumbles After European Regulators Unexpectedly Reject Alzheimer's Drug
    Via Investor's Business Daily
    The 3 Best Neuroscience Biotech Stocks to Buy Now
    Via InvestorPlace
    Week In Review: Samsung Biologics Signs $1 Billion Manufacturing Contract With US Biopharma
    Via Talk Markets
    3 Highly Rated Biotech Stocks for Your July Buy List
    Via InvestorPlace
    Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst
    Via Benzinga
    Exposures Product Safety
    Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, Eisai
    Via Investor's Business Daily
    Eli Lilly's Donanemab Gains Favorable FDA Advisory Verdict, Boosting Stock Potential, Says BofA Analyst
    Via Benzinga
    Exposures Product Safety
    Eli Lilly Drags Alzheimer's Stocks Prothena, Eisai Lower Despite FDA Win
    Via Investor's Business Daily
    Exposures Product Safety
    Eli Lilly Rises Again, As FDA Panel Mulls Biogen-Rivaling Alzheimer's Drug
    Via Investor's Business Daily
    Exposures Product Safety
    The 3 Most Undervalued Pharma Stocks to Buy in June 2024
    Via InvestorPlace
    Topics Economy
    Exposures Economy
    Biogen Stock Continues Its 20% Sprint On A Twist In Alzheimer's Treatment
    Via Investor's Business Daily
    Two Notable Biogen Drugs Walloped Sales Forecasts. Will It Be Enough To Reverse Biogen Stock's Decline?
    Via Investor's Business Daily
    Topics Earnings
    Exposures Financial
    3 Stocks Wall Street Is Ignoring (But You Shouldn’t): April Edition
    Via InvestorPlace
    Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback
    Via Investor's Business Daily
    Exposures Product Safety
    3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
    Via InvestorPlace
    Week In Review: I-Mab Morphs Into US-Only Company; Sells China Assets For $80 Million
    Via Talk Markets
    Brain Disease Cures: 3 Neuroscience Stocks Targeting Revolutionary Breakthroughs
    Via InvestorPlace
    Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
    Via Investor's Business Daily
    3 Aging Population Stocks to Profit from the Boomer Generation
    Via InvestorPlace
    Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others
    Via Benzinga
    Quest For Alzheimer's Cure: Big Biotech Breakthroughs, But The Race Is Just Beginning
    Via Investor's Business Daily
    3 Biotech Moonshots to Bet on the Future of Health
    Via InvestorPlace
    Topics Intellectual Property
    Exposures Intellectual Property
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.